Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

ClinicalTrials.gov ID: NCT04732871

Public ClinicalTrials.gov record NCT04732871. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.

Study identification

NCT ID
NCT04732871
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,720 participants

Conditions and interventions

Eligibility (public fields only)

Age range
60 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 14, 2021
Primary completion
Jun 5, 2022
Completion
Feb 18, 2027
Last update posted
Jul 13, 2026

2021 – 2027

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
18
Facility City State ZIP Site status
GSK Investigational Site Mobile Alabama 36608
GSK Investigational Site Phoenix Arizona 85020
GSK Investigational Site Riverside California 92503
GSK Investigational Site San Diego California 92103
GSK Investigational Site Coral Gables Florida 33134
GSK Investigational Site Fort Myers Florida 33912
GSK Investigational Site Sarasota Florida 34243
GSK Investigational Site The Villages Florida 32162
GSK Investigational Site Evansville Indiana 47714
GSK Investigational Site Wichita Kansas 67226
GSK Investigational Site Richfield Minnesota 55423
GSK Investigational Site Kansas City Missouri 64114
GSK Investigational Site Rochester New York 14609
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Spartanburg South Carolina 29303
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Norfolk Virginia 23502
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04732871, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 13, 2026 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04732871 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →